



Semaphorin 3A potentiates the profibrotic effects of transforming growth factor- β 1 in the cornea

Kye-Im Jeon ^a, Keith Nehrke ^b, Krystal R. Huxlin ^{a,*}

^a Flaum Eye Institute, USA

^b Department of Medicine, University of Rochester, Rochester, NY, USA

ARTICLE INFO

Article history:

Received 24 September 2019

Accepted 12 October 2019

Available online 24 October 2019

Keywords:

Keratocytes
Wound healing
Stroma
Fibroblasts
Epithelium
Scarring

ABSTRACT

Corneal scarring is a major cause of blindness worldwide with few effective therapeutic options. Finding a treatment would be of tremendous public health benefit, but requires a thorough understanding of the complex interactions that underlie this phenomenon. Here, we tested the hypothesis that the large increase in expression of Semaphorin 3A (SEMA3A) in corneal wounds contributes to the development of stromal fibrosis. We first verified this increased expression *in vivo*, in a cat model of photorefractive keratectomy-induced corneal wounding. We then examined the impact of adding exogenous SEMA3A to cultured corneal fibroblasts, and assessed how this affected the ability of transforming growth factor- β 1 (TGF- β 1) to induce their differentiation into myofibroblasts. Finally, we examined how siRNA knockdown of endogenous SEMA3A affected these same phenomena. We found exogenous SEMA3A to significantly potentiate TGF- β 1's profibrotic effects, with only a minimal contribution from cell-intrinsic SEMA3A. Our results suggest a previously unrecognized interaction between SEMA3A and TGF- β 1 in the wounded cornea, and a possible contribution of SEMA3A to the regulation of tissue fibrosis and remodeling in this transparent organ.

© 2019 Elsevier Inc. All rights reserved.

1. Introduction

Corneal injury, infection and surgery lead to fibrosis and scarring, which when severe, is a primary causes of vision loss and blindness world-wide [1]. Yet clinically, there are few effective means of preventing fibrosis or treating established corneal scars [2]. This motivates ongoing scientific effort to unravel the complex cell and molecular factors that control fibrotic and scarring components of corneal wound healing. After corneal damage, stromal keratocytes are exposed to multiple growth factors and cytokines, including transforming growth factor (TGF)- β 1, the strongest known pro-fibrotic agent [3,4]. While the transparent keratocytes in and around the damaged zone undergo apoptosis, distant

keratocytes transform into activated fibroblasts [5], migrating into the wound area, where exposure to TGF- β 1 stimulates them to become myofibroblasts [6,7]. Myofibroblasts - while helping to close the wound [8,9] - are no longer transparent [10–12] and they produce and remodel the extracellular matrix (ECM) in ways that further decreases transparency [13], causing vision loss and blindness. TGF- β 1 plays a key role in this process by regulating expression of multiple genes that cause myofibroblast differentiation, and control their actions [10,14,15]. However, the profibrotic actions of TGF- β 1 can be potentiated by such molecules as platelet-derived growth factor [10,16] and connective tissue growth factor [17–20].

Corneal wounding also causes levels of Semaphorin 3A (SEMA3A) to rise dramatically (10-fold) in the epithelium [21], helping to regulate epithelial healing [22]. In parallel, epidermal growth factor (EGF) released from wounded corneal epithelial cells up-regulates the expression of SEMA3A in stromal fibroblasts [23], but the role of this abundant wound healing molecule in the stroma is unknown. Here, we begin to fill this gap. The Semaphorin family [24] includes a large, diverse set of secreted, cell surface-attached, membrane-bound proteins [25]. SEMA3A is known to collapse the actin cytoskeleton and disassemble F-actin in multiple cell

Abbreviations: α -SMA, alpha smooth muscle actin; COL, collagen; DAPI, 4',6-diamidino-2-phenylindole; DMEM, Dulbecco's modified Eagle's medium; dPBS, Dulbecco's phosphate-buffered saline; ECM, extracellular matrix; EDA, extra domain A; EGF, epidermal growth factor; FBS, fetal bovine serum; FGF, fibroblast growth factor; NBCS, newborn calf serum; PRK, photorefractive keratectomy; SEMA3A, semaphorin 3A; TGF- β 1, transforming growth factor-beta 1.

* Corresponding author. Flaum Eye Institute, 210 Crittenden Blvd., Box 314, Rochester, 14642, NY, USA.

E-mail address: khuxlin@ur.rochester.edu (K.R. Huxlin).

types [26,27]. Given the cytoskeletal reorganization involved in the differentiation of myofibroblasts during wound healing, a logical question was whether SEMA3A contributes to this process. We first verified that SEMA3A expression is upregulated in corneal epithelial and stromal cells in our well-established, *in vivo* cat wound-healing model [17,28–32]. We then assayed the expression of SEMA3A in cultured cat corneal fibroblasts before examining the effects of SEMA3A on TGF- β 1-induced myofibroblast differentiation and ECM production. Finally, we knocked-down SEMA3A in cultured cat corneal fibroblasts with siRNA treatment to critically examine the residual ability of these cells to respond to TGF- β 1.

2. Materials and methods

2.1. *In vivo* experiments

Animal procedures were conducted according to the NIH Guide for the Care and Use of Laboratory Animals, with protocols approved by the University of Rochester Committee on Animal Research (Assurance Number: A-3292-01). Cats were obtained from a research breeding colony managed by Liberty Research Inc. (Waverley, NY, USA). As recently described [33], photorefractive keratectomy (PRK) was performed on 6 eyes from 3 young (1–2 years old) adult, domestic, short-hair cats (*felis catus*). Eyes obtained in this recent paper were studied presently at 4 weeks post-PRK, as this timepoint exhibited a large, fibrotic layer in the ablation zone; 5 additional eyes served as unoperated, normative controls.

2.1.1. Laser ablation

PRK was performed by the same refractive surgeon (HH), with a commercial excimer laser (Technolas 217, Zyoptix 4.14, Bausch & Lomb Inc., Bridgewater, NJ, USA) in the center of each cat cornea, following manual debridement of the epithelium [33]. A 10D myopic ablation was performed over a 6 mm optical zone, under topical (Proparacaine 0.5%, Falcon Pharmaceuticals Ltd., Fort Worth, TX, USA) and surgical anesthesia (5 mg/kg Ketamine+0.04 mg/kg Dexmedetomidine Hydrochloride). Immediately post-PRK, cat eyes were rinsed with balanced salt solution (BSS, Alcon Inc., Fort Worth, TX, USA) followed by a drop of antibiotics (Neomycin, Polymyxin B Sulphate, Gramicidin Ophthalmic Solution USP, Bausch & Lomb Inc., Bridgewater, NJ, USA) twice daily for 2 weeks.

2.1.2. Histology and immunohistochemistry

After euthanasia, the corneas were excised and immersion fixed in 1% paraformaldehyde in 0.1 M phosphate buffered saline (PBS), pH 7.4 for 10 min. They were cryoprotected in 30% sucrose in 0.1 M PBS at 4 °C for 2 days and serial-sectioned at 20 μ m using a cryostat (2800 Frigocut E, Leica Microsystems GmbH, Wetzlar, Germany), collected on gelatin-coated glass slides, and stored at –20 °C until stained. Sections in the ablation center (or the geometric center of unoperated corneas) were selected for immunohistochemistry; they were co-incubated with a primary mouse monoclonal anti- α -SMA (1:100; Thermo Fisher Scientific, Waltham, MA, USA) and a feline-specific, rabbit polyclonal anti-SEMA3A antibody (1:100; YenZym Antibodies LLC., South San Francisco, CA, USA) overnight at 4 °C. Some sections from each treatment group were also incubated overnight with PBS (Cellgro™, Manassas, VA, USA) containing 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) as a negative control. Secondary antibodies (Alexa-Fluor-488 conjugated to goat anti-rabbit IgG and Alexa-Fluor-555 conjugated to goat anti-mouse IgG, both at 1:400; Invitrogen, Carlsbad, CA, USA) were applied at room temperature for 2 h. Sections were cover-slipped with Vectashield Mounting Medium containing 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc., Burlingame, CA, USA).

2.2. *In vitro* experiments

2.2.1. Isolation and culture of primary cat corneal fibroblasts

As previously described [29,30], fresh eyeballs were obtained immediately post-mortem. The corneal epithelium and endothelium were scraped off, the stroma double-enzyme digested, then centrifuged at 3000 rpm for 10 min, re-suspended in fibroblast growth factor (FGF)-containing medium (PromoCell GmbH, Heidelberg, Germany), counted and seeded onto culture plates (Greiner Bio-one; Kremsmünster, Austria). Passage 6 to 7 cells were used for all experiments, which were performed at least in triplicate.

2.2.2. SEMA3A expression

Cat corneal fibroblasts (3×10^5 cells/6-cm dish in Dulbecco's modified Eagle's medium (DMEM)/F12 (Cellgro™, Manassas, VA, USA), 15% serum [5% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA) + 10% newborn calf serum (NBCS; Gibco Laboratories, Gaithersburg, MD, USA)] and 1% [vol/vol] penicillin/streptomycin (Cellgro™, Manassas, VA, USA). After attachment, the serum content of the medium was decreased to 0.5% (0.25% FBS+0.25% NBCS) for 1 day to promote cellular quiescence. The cells were then treated with 1 ng/ml TGF- β 1 (R&D Systems Inc., Minneapolis, MN, USA) and grown for 3 days. The supernatant was then collected, centrifuged at 1000g for 5 min to remove detached cells and large debris and concentrated using ultra 50k Molecular Weight Cutoff (Millipore-Sigma, Burlington, MA, USA). The remaining plated cells were washed with 1x Dulbecco's phosphate-buffered saline (dPBS; Cellgro™, Manassas, VA, USA), drained and mixed with 2x SDS loading buffer to generate whole-cell lysates. The concentrated supernatants and whole-cell lysates were processed for Western blotting. Ponceau S staining was used to verify that the same amount of supernatant was run on the gels, which were stained with a mouse monoclonal anti- α -SMA antibody (1:10,000; Thermo Fisher Scientific, Waltham, MA, USA) and a feline-specific, rabbit polyclonal anti-SEMA3A antibody (1:500; YenZym Antibodies LLC., South San Francisco, CA, USA). Levels of β -Tubulin served as a loading control, assayed using a mouse monoclonal β -Tubulin antibody (1:5000; Santa Cruz Inc., Dallas, TX, USA). Finally, 25 ng recombinant human SEMA3A (R&D Systems Inc., Minneapolis, MN, USA) was used as a reference with which to contrast native SEMA3A in cat corneal stromal cells and supernatant. The membranes were scanned with a Chemi-doc machine (Bio-Rad, Hercules, CA, USA) and the resulting images were imported into Image J (NIH, USA) for measurement of relative protein expression.

2.2.3. Effects of exogenous SEMA3A and TGF- β 1

Quiescent corneal fibroblasts (8×10^4 cells/well in 6-well plates) were pretreated with 100 ng/ml of recombinant SEMA3A (see [Supplementary Fig. 1](#) for dose justification) for 30 min, with or without 1 ng/ml recombinant human TGF- β 1 (3-days incubation). Western blots were used to quantify the relative expression of Type 1 collagen (COL1 polyclonal antibody 1:2000; kindly provided by Dr. Larry W. Fisher, NIH, Bethesda, MD), total Fibronectin (t-FN polyclonal antibody 1:2000; Santa Cruz Inc., Dallas, TX, USA), extracellular domain A-fibronectin (EDA-FN monoclonal antibody 1:2000; Santa Cruz Inc., Dallas, TX, USA) and α -SMA (as above). Levels of β -actin (mouse monoclonal antibody 1:10,000; Santa Cruz Inc., Dallas, TX, USA) were used as a loading control. Imaging and densitometry were performed as described above.

2.2.4. Effects of Sema3A siRNA

Cat corneal fibroblasts (1.5×10^6 /10 mm dish) were seeded in DMEM/F12, 5% FBS+10% NBCS in the absence of penicillin/streptomycin. After 1 day, cells were transfected with Sema3A siRNA (D-

058440-04, GE Healthcare Dharmacon Inc., Lafayette, CO, USA) or control siRNA (D-001810-01, GE Healthcare Dharmacon Inc., Lafayette, CO, USA). Oligofectamine (Invitrogen, Carlsbad, CA, USA) reagent was used to perform siRNA transfections as per manufacturer's instructions. One day after transfection, the cells were harvested and re-plated at a density of 8×10^4 /6-well plate and treated with/without 1 ng/ml TGF- β 1 for 3 days before harvesting and Western blots to estimate the expression of SEMA3A, α -SMA, COL1, EDA-FN and t-FN relative to those of β -actin and β -tubulin, as described above.

About 24 h after transfection with control siRNA or Sema3A siRNA, 1×10^4 cells/ml of transfected fibroblasts of each type were seeded in separate, 4-well Lab-Tek II chamber slides (Thermo Fisher Scientific, Waltham, MA, USA). They were then treated with/without 1 ng/ml TGF- β 1 and cultured for another 3 days before fixing with 4% formaldehyde (Thermo Fisher Scientific, Waltham, MA, USA) for 15 min at room temperature. The media chambers were removed, the slides were rinsed with PBS +5% dextrose (Sigma-Aldrich, St. Louis, MO, USA) and post-fixed with absolute acetone (Sigma-Aldrich, St. Louis, MO, USA) at -20°C for 10 min. After blocking with 5% normal horse serum (Sigma-Aldrich, St. Louis, MO, USA) for 30 min, the slides were incubated overnight at 4°C in a humid chamber with the primary mouse monoclonal α -SMA antibody described earlier (1:100). The secondary antibody was goat anti-mouse IgG (H&L) Alexa-Fluor-488 (1:200; Invitrogen, Carlsbad, CA, USA). To stain actin stress fibers, PhalloidinCruzFluor-555 conjugate (1:500; Santa Cruz Inc., Dallas, TX, USA) was added. After rinsing, slides were coverslipped with Vectashield Antifade Mounting Medium containing DAPI. Fluorescence and phase contrast images were acquired using an Olympus IX73 microscope and a DP80 Dual-Mono camera (Olympus America Inc., Center Valley, PA, USA).

2.3. Statistical analyses

In order to evaluate differences in protein expression levels on Western blots, when three or more groups were compared, intergroup differences were tested with a one- or two-way analyses of variance (ANOVA), followed by Tukey's post-hoc tests, if appropriate. When only two groups were compared, a two-tailed

Student's t-test was performed. A probability of error of $p < 0.05$ was considered statistically significant.

3. Results

3.1. Persistent increase in corneal SEMA3A expression after PRK

Intact, adult cat cornea exhibited its strongest staining for SEMA3A in the epithelium (Fig. 1A, C). Stromal keratocytes only stained faintly for SEMA3A (Fig. 1A, C). By 4 weeks after PRK, as previously reported [33], a strong zone of α -SMA-positive cells (Fig. 1E, H) was still evident under the healed, central corneal epithelium. The epithelium continued to stain strongly for SEMA3A, but even at this late stage post-insult, cells in the α -SMA-positive zone stained strongly for SEMA3A (Fig. 1E, G). While some were α -SMA-positive, the wound area had numerous cells – presumably fibroblasts – positive for SEMA3A but negative for α -SMA (white arrows in Fig. 1E, G, H), clustered both below and above the α -SMA-positive zones, but restricted to the ablation zone. The peripheral cornea exhibited immunostaining that was not qualitatively different from that in intact/unoperated corneas (as in Fig. 1A–D).

3.2. Cultured corneal fibroblasts and myofibroblasts synthesize and secrete SEMA3A

We observed three different isoforms of SEMA3A (125 kDa, 95 kDa and 65 kDa) in fibroblast lysates (Fig. 2, lane 1) and the major secreted form of SEMA3A, the 65 kDa isoform [34,35], was dominant in their supernatant (Fig. 2, lane 3). After adding TGF- β 1 to these cells, there was increased expression of α -SMA in the lysates (Fig. 2, lane 2), suggesting that fibroblasts had differentiated into myofibroblasts. Levels of all 3 isoforms of SEMA3A (125 kDa, 95 kDa and 65 kDa) were similarly expressed in myofibroblast lysates, and their supernatant contained similar levels of the 65 kDa isoform as the fibroblast supernatant. These observations confirm that fibroblasts and myofibroblasts derived from primary corneal keratocytes express detectable levels of several SEMA3A isoforms, and secrete similar amounts of 65 kDa SEMA3A.




Fig. 1. *In vivo* expression of SEMA3A in feline corneas. **A.** Unoperated, cornea triple labelled for SEMA3A, α -SMA and DAPI. The epithelium is uppermost. Individual stains (monochrome) are shown in **B–D**. Keratocytes (arrowed) are faintly SEMA3A positive. Note total absence of α -SMA staining. **E.** Photograph of a central cat cornea 4 weeks after PRK, triple labelled as in **A**. Individual stains are shown in **F–H**. Arrows indicate α -SMA-negative cells that are strongly SEMA3A-positive. Note the zone of cellular hyper-density below the α -SMA-positive layer (demarcated with yellow line), where a significant proportion of cells [putative fibroblasts] are SEMA3A-positive.




Fig. 2. Basal expression of SEMA3A in cultured cat corneal fibroblasts and myofibroblasts. Representative Western blot showing similar, relative SEMA3A expression levels in whole cell lysates and concentrated supernatants (S/N) of cat corneal fibroblasts (F) and myofibroblasts (M). Expression of α -SMA was used as an indicator of myofibroblast differentiation in the cell lysates.

3.3. SEMA3A potentiates the pro-fibrotic effects of TGF- β 1 in corneal fibroblasts

After 3 days of culture in the absence of any treatment, basal levels of EDA-FN and α -SMA in cat corneal fibroblasts were close to zero, while those of COL1 and t-FN were low but distinctly above zero (Fig. 3A, lane 1). A dose-response test for SEMA3A determined that this molecule was not, by itself, able to induce myofibroblast differentiation (morphologically-determined, data not shown) or upregulate expression of α -SMA at doses ranging from 10 to 500 ng/ml (Supplementary Fig. 1). This lack of effect was replicated for 100 ng/ml SEMA3A (the dose selected for present experiments)

and all pro-fibrotic molecules of interest [2(treatment) \times 4(molecules) ANOVA with repeated measures across molecules: $F(1,31) = 0$, $p = 1$; Fig. 3A, lane 2; Fig. 3B]. In contrast, addition of TGF- β 1 alone significantly increased relative expression of pro-fibrotic molecules compared to baseline [2(treatment) \times 4(molecules) ANOVA: $F(1,31) = 47$, $p = 0.0005$; Fig. 3A, lane 4; Fig. 3B]. However, the biggest effect occurred when fibroblasts were exposed to 100 ng/ml SEMA3A + 1 ng/ml TGF- β 1 (Fig. 3A, lane 3; Fig. 3B); this significantly increased expression of all pro-fibrotic markers relative to baseline [2(treatment) \times 4(molecules) ANOVA: $F(1,31) = 137.67$, $p < 0.0001$], as well as over TGF- β 1 alone [2(treatment) \times 4(molecules) ANOVA: $F(1,31) = 12$, $p = 0.0134$]. Combined administration of SEMA3A/TGF- β 1 generated levels of pro-fibrotic molecules (mean \pm SD) 1.7 ± 0.4 fold higher than following incubation with 1 ng/ml TGF- β 1 alone, and this was consistent across all molecules examined.

3.4. SEMA3A effects are cell non-autonomous

Cells transfected with control siRNA expressed normal levels of the 125 kDa, 95 kDa and 65kDa isoforms of SEMA3A (Fig. 3C, lane 1), continuing to do so even after addition of 1 ng/ml TGF- β 1 (Fig. 3C, lane 2). This was consistent with our earlier result (Fig. 2). In contrast, corneal fibroblasts transfected with Sema3a siRNA showed diminished expression of the 125 kDa and 95 kDa isoforms of SEMA3A (Fig. 3C, lane 3) compared to cells transfected with control siRNA. This also continued to hold true after stimulation with TGF- β 1 (Fig. 3C, lane 4).

With respect to synthesis of pro-fibrotic molecules, basal levels of t-FN and COL1 were relatively unchanged by Sema3a siRNA (Fig. 3D, lanes 1 & 3), suggesting that cell-autonomous SEMA3A does not regulate their baseline expression. Addition of TGF- β 1 elicited the expected increased synthesis of t-FN, COL-1, EDA-FN




Fig. 3. SEMA3A potentiates TGF- β 1's profibrotic effects in cultured cat corneal fibroblasts. **A.** Representative Western blot showing protein levels for COL1, t-FN, EDA-FN and α -SMA in cells treated with recombinant human SEMA3A with/without TGF- β 1. Adding SEMA3A potentiated TGF- β 1-induced increases in EDA-FN, t-FN, COL1 and α -SMA relative to TGF- β 1 alone. **B.** Plot of relative densitometry data for EDA-FN, t-FN, COL1 and α -SMA with respect to β -actin. Data are means \pm SEM over 4 experiments. **ANOVA relative to baseline, $p < 0.0005$. *ANOVA between 2 treatment groups, $p < 0.05$. **C.** Representative Western blot showing SEMA3A levels in cells transfected with Sema3a siRNA or control (non-targeting) siRNA. **D.** Representative Western blot showing relative levels of COL1, t-FN, EDA-FN and α -SMA in fibroblasts transfected with control siRNA or Sema3a siRNA and cultured with/without TGF- β 1. **E.** Plot of relative densitometry data for EDA-FN, t-FN, COL1 and α -SMA with respect to β -actin. Data are means \pm SEM over 3 experiments. *ANOVA relative to baseline, $p < 0.05$. ns ANOVA between 2 treatment groups, $p = 0.227$.

and α -SMA in both control (Fig. 3D, lane2) and Sema3A siRNA-transfected cells (Fig. 3D, lane 4). A 2(baseline versus TGF- β 1) \times 4 (molecules) repeated measures ANOVA for the control siRNA had an $F(1,23) = 14.68$, $p = 0.0186$. The same ANOVA for the Sema3A siRNA was also significant [$F(1,23) = 13.38$, $p = 0.0216$]. As such, when contrasting TGF- β 1 treatment in the control versus Sema3A siRNA groups, the repeated measures ANOVA showed no main effect of treatment [$F(1,23) = 2.03$, $p = 0.227$]. However, there was a main effect of molecules examined [$F(3,23) = 10.33$, $p = 0.00121$]. Indeed, while post-hoc t-tests revealed no significant change in COL1 or total-FN expression, Sema3A siRNA treated cells expressed less EDA-FN ($t_2 = 4.47$, $p = 0.0466$) and α -SMA ($t_2 = 4.52$, $p = 0.0456$) than their control siRNA counterparts. This was confirmed by immunocytochemistry in cultured cells, where morphologically, Sema3A siRNA transfected fibroblasts maintained the ability to differentiate into myofibroblasts (Fig. 4). But although these large, multipolar cells had prominent stress fibers upon Phalloidin staining (Fig. 4B), they stained more faintly for α -SMA compared to control-siRNA-transfected cells exposed to TGF- β 1 (Fig. 4A).

4. Discussion

After corneal injury, wound healing generates fibrosis, which can induce scar formation and decrease transparency of this critical ocular lens [10]. Corneal fibrosis is characterized first by transformation of keratocytes into fibroblast, thence into myofibroblast, which increase synthesis and abnormal deposition of ECM components, stimulated by a variety of growth factors and cytokines [10,20]. TGF- β 1 is the strongest-known, profibrotic growth factor, but SEMA3A is also greatly upregulated in corneal wounds [21,22]. While SEMA3A plays key roles in axonal guidance [36,37] cancer progression [38–40] and kidney injury [41,42], only scant information exists about its role(s) in the wounded cornea.

In the undamaged cat cornea, epithelial cells and to a lesser degree stromal keratocytes, appeared to natively express this molecule, as previously shown in rodents [43]. Four weeks after PRK however, SEMA3A expression dramatically increased in both

the epithelium and stromal cells within the wound area, again consistent with prior observations in rodent models of corneal wounding [21,22]. SEMA3A is first synthesized as a pro-protein; differential proteolytic processing then generates multiple isoforms that can differ between species and cell types [34]. Cat corneal fibroblasts and myofibroblasts preferentially and similarly expressed the 125 kDa, 95 kDa and 65 kDa isoforms of SEMA3A. The 65 kDa isoform dominated in the supernatants, consistent with the notion that it is likely the secreted form of this molecule [34,35]. Of relevance here, previous studies reported that expression of SEMA3A is regulated by other growth factors, including EGF [23] and hepatocyte growth factor/FGF2 [44]. Our data suggest that SEMA3A expression by stromal fibroblasts is not regulated by TGF- β 1. However, keratocytes *in vivo* stained more faintly for SEMA3A than fibroblasts or myofibroblasts after PRK, suggesting that TGF- β 1 could still influence levels of SEMA3A in stromal keratocytes.

Key to our initial question, our data show that exogenously-applied SEMA3A works synergistically with TGF- β 1 to potentiate differentiation of corneal fibroblasts into myofibroblasts, and the ability of the latter to upregulate synthesis of α -SMA and extracellular matrix molecules (EDA-FN, COL1 and t-FN). This is in spite of the fact that exogenous SEMA3A alone does not seem to differentiate cat corneal fibroblasts into myofibroblasts. Consistent with this, knocking down endogenous SEMA3A with siRNA did not eliminate the cells' ability to differentiate into myofibroblasts or synthesize profibrotic molecules. However, exogenously-added SEMA3A and TGF- β 1 together significantly increased the expression of EDA-FN, t-FN, COL1 and α -SMA over levels obtained from TGF- β 1 stimulation alone.

Thus, in the cornea, elevated secretion of SEMA3A after injury - likely from the epithelium [21,22] - potentiates TGF- β 1's profibrotic effects in activated fibroblasts. Although further studies are needed to determine how SEMA3A interacts with TGF- β 1 to generate the synergistic effects observed in the present experiments, a possible mechanism may involve neuropilin-1, a SEMA3A receptor shown to act as a co-receptor for TGF- β 1 in cancer cells [45]. Nonetheless, the present work describes a hitherto




Fig. 4. Sema3A siRNA knockdown decreases immunocytochemical expression of α -SMA in cultured corneal myofibroblasts. **A.** Phase contrast images (top row) show a change from fibroblastic to myofibroblastic morphologies in both cells transfected with control and Sema3A siRNA, but α -SMA staining (green in bottom row) is decreased in Sema3A siRNA-treated cells. **B.** Phalloidin staining of different regions on the same plates as in A shows persistence of F-actin fibers and clear morphological characteristics of larger myofibroblasts in the two plates treated with TGF- β 1, even when α -SMA expression was decreased, as in the Sema3A siRNA + TGF- β 1 condition.

unrecognized relationship between SEMA3A and TGF- β 1 in the wounded cornea, and suggests a possible contribution of cell non-autonomous SEMA3A to the regulation of tissue fibrosis and remodeling in this transparent organ. Finally, given SEMA3A's inhibitory effect on neurite outgrowth [36,37] and recent work showing that regenerating corneal nerves avoid corneal wound areas and the myofibroblasts they contain [33,46] the present results also lay an interesting foundation for future investigations into roles that SEMA3A may play at the interface between regenerating neurons and fibrotic wound healing.

Declaration of competing interest

The authors have no proprietary interest in any devices or pharmacologics used in this study.

Acknowledgments

This research was supported by the National Eye Institute of the National Institutes of Health (R01 EY015836 and Core Grant P30 EY001319 to the Center for Visual Science) and an unrestricted grant to the University of Rochester's Department of Ophthalmology from the Research to Prevent Blindness Foundation. The authors thank Dr. Holly Hindman, Ms. Margaret DeMagistris and Ms. Chrys Callan for performing PRK on live cats, Mrs. Tracy Bubel for tissue processing, and Mrs. Thurma McDaniel for immunocytochemical staining.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbrc.2019.10.107>.

Transparency document

Transparency document related to this article can be found online at <https://doi.org/10.1016/j.bbrc.2019.10.107>.

References

- [1] M.S. Oliva, T. Schottman, M. Gulati, Turning the tide of corneal blindness, *Indian J. Ophthalmol.* 60 (2012) 423–427.
- [2] S.L. Wilson, A.J. El Haj, Y. Yang, Control of scar tissue formation in the cornea: strategies in clinical and corneal tissue engineering, *J. Funct. Biomater.* 3 (2012) 642–687.
- [3] J.V. Jester, P.A. Barry-Lane, H.D. Cavanagh, W.M. Petroll, Induction of alpha-smooth muscle actin expression and myofibroblast transformation in cultured corneal keratocytes, *Cornea* 15 (1996) 505–516.
- [4] M. Vesaluoma, A.M. Teppo, C. Gronhagen-Riska, T. Tervo, Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy, *Curr. Eye Res.* 16 (1997) 19–25.
- [5] M.E. Fini, Keratocyte and fibroblast phenotypes in the repairing cornea, *Prog. Retin. Eye Res.* 18 (1999) 529–551.
- [6] J.V. Jester, W.M. Petroll, H.D. Cavanagh, Corneal stromal wound healing in refractive surgery: the role of myofibroblasts, *Prog. Retin. Eye Res.* 18 (1999) 311–356.
- [7] J.A. West-Mays, D.J. Dwivedi, The keratocyte: corneal stromal cell with variable repair phenotypes, *Int. J. Biochem. Cell Biol.* 38 (2006) 1625–1631.
- [8] J.V. Jester, M.M. Rodrigues, I.M. Herman, Characterization of avascular corneal wound healing fibroblasts. New insights into the myofibroblast, *Am. J. Pathol.* 127 (1987) 140–148.
- [9] I.A. Darby, B. Laverdet, F. Bonte, A. Desmouliere, Fibroblasts and myofibroblasts in wound healing, *Clin. Cosmet. Investig. Dermatol.* 7 (2014) 301–311.
- [10] S.E. Wilson, Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency, *Exp. Eye Res.* 99 (2012) 78–88.
- [11] J.V. Jester, D. Brown, A. Pappa, V. Vasilioiu, Myofibroblast differentiation modulates keratocyte crystallin protein expression, concentration, and cellular light scattering, *Investig. Ophthalmol. Vis. Sci.* 53 (2012) 770–778.
- [12] J.V. Jester, T. Moller-Pedersen, J. Huang, C.M. Sax, W.T. Kays, H.D. Cavanagh, W.M. Petroll, J. Piatigorsky, The cellular basis of corneal transparency: evidence for 'corneal crystallins', *J. Cell Sci.* 112 (Pt 5) (1999) 613–622.
- [13] J.R. Hassell, D.E. Birk, The molecular basis of corneal transparency, *Exp. Eye Res.* 91 (2010) 326–335.
- [14] J.V. Jester, W.M. Petroll, P.A. Barry, H.D. Cavanagh, Expression of alpha-smooth muscle (alpha-SM) actin during corneal stromal wound healing, *Investig. Ophthalmol. Vis. Sci.* 36 (1995) 809–819.
- [15] A. Desmouliere, A. Geinoz, F. Gabbiani, G. Gabbiani, Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts, *J. Cell Biol.* 122 (1993) 103–111.
- [16] V. Singh, F.L. Barbosa, A.A. Torricelli, M.R. Santhiago, S.E. Wilson, Transforming growth factor beta and platelet-derived growth factor modulation of myofibroblast development from corneal fibroblasts in vitro, *Exp. Eye Res.* 120 (2014) 152–160.
- [17] K.I. Jeon, R.P. Phipps, P.J. Sime, K.R. Huxlin, Inhibitory effects of PPARgamma ligands on TGF-beta1-induced CTGF expression in cat corneal fibroblasts, *Exp. Eye Res.* 138 (2015) 52–58.
- [18] G.R. Grotendorst, Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts, *Cytokine Growth Factor Rev.* 8 (1997) 171–179.
- [19] K.E. Lipson, C. Wong, Y. Teng, S. Spong, CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis, *Fibrogenesis Tissue Repair* 5 (2012) S24.
- [20] A.V. Ljubimov, M. Saghizadeh, Progress in corneal wound healing, *Prog. Retin. Eye Res.* 49 (2015) 17–45.
- [21] Z. Cao, H.K. Wu, A. Bruce, K. Wollenberg, N. Panjwani, Detection of differentially expressed genes in healing mouse corneas, using cDNA microarrays, *Investig. Ophthalmol. Vis. Sci.* 43 (2002) 2897–2904.
- [22] N. Morishige, J.A. Ko, Y. Morita, T. Nishida, Expression of semaphorin 3A in the rat corneal epithelium during wound healing, *Biochem. Biophys. Res. Commun.* 395 (2010) 451–457.
- [23] J.A. Ko, N. Morishige, R. Yanai, T. Nishida, Up-regulation of semaphorin 3A in human corneal fibroblasts by epidermal growth factor released from cocultured human corneal epithelial cells, *Biochem. Biophys. Res. Commun.* 377 (2008) 104–108.
- [24] A.L. Kolodkin, D.J. Matthes, C.S. Goodman, The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules, *Cell* 75 (1993) 1389–1399.
- [25] R.J. Pasterkamp, A.L. Kolodkin, Semaphorin junction: making tracks toward neural connectivity, *Curr. Opin. Neurobiol.* 13 (2003) 79–89.
- [26] J.A. Brown, P.C. Bridgman, Disruption of the cytoskeleton during Semaphorin 3A induced growth cone collapse correlates with differences in actin organization and associated binding proteins, *Dev Neurobiol* 69 (2009) 633–646.
- [27] R.J. Hung, J.R. Terman, Extracellular inhibitors, repellents, and semaphorin/plexin/MICAL-mediated actin filament disassembly, *Cytoskeleton (Hoboken)* 68 (2011) 415–433.
- [28] K.I. Jeon, R.P. Phipps, P.J. Sime, K.R. Huxlin, Antifibrotic actions of peroxisome proliferator-activated receptor gamma ligands in corneal fibroblasts are mediated by beta-catenin-regulated pathways, *Am. J. Pathol.* 187 (2017) 1660–1669.
- [29] K.I. Jeon, A. Kulkarni, C.F. Woeller, R.P. Phipps, P.J. Sime, H.B. Hindman, K.R. Huxlin, Inhibitory effects of PPARgamma ligands on TGF-beta1-induced corneal myofibroblast transformation, *Am. J. Pathol.* 184 (2014) 1429–1445.
- [30] K.R. Huxlin, H.B. Hindman, K.I. Jeon, J. Buhren, S. MacRae, M. DeMagistris, D. Ciuffo, P.J. Sime, R.P. Phipps, Topical rosiglitazone is an effective anti-scarring agent in the cornea, *PLoS One* 8 (2013), e70785.
- [31] J. Buhren, L. Nagy, J.N. Swanton, S. Kenner, S. MacRae, R.P. Phipps, K.R. Huxlin, Optical effects of anti-TGFbeta treatment after photorefractive keratectomy in a cat model, *Investig. Ophthalmol. Vis. Sci.* 50 (2009) 634–643.
- [32] L.J. Nagy, S. MacRae, G. Yoon, M. Wyble, J. Wang, I. Cox, K.R. Huxlin, Photorefractive keratectomy in the cat eye: biological and optical outcomes, *J. Cataract Refract. Surg.* 33 (2007) 1051–1064.
- [33] K.I. Jeon, H.B. Hindman, T. Bubel, T. McDaniel, M. DeMagistris, C. Callan, K.R. Huxlin, Corneal myofibroblasts inhibit regenerating nerves during wound healing, *Sci. Rep.* 8 (2018) 12945.
- [34] R.H. Adams, M. Lohrum, A. Klostermann, H. Betz, A.W. Puschel, The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing, *EMBO J.* 16 (1997) 6077–6086.
- [35] J. De Wit, F. De Winter, J. Klooster, J. Verhaagen, Semaphorin 3A displays a punctate distribution on the surface of neuronal cells and interacts with proteoglycans in the extracellular matrix, *Mol. Cell. Neurosci.* 29 (2005) 40–55.
- [36] J.A. Raper, Semaphorins and their receptors in vertebrates and invertebrates, *Curr. Opin. Neurobiol.* 10 (2000) 88–94.
- [37] Y. Luo, D. Raible, J.A. Raper, Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones, *Cell* 75 (1993) 217–227.
- [38] A. Chedotal, Chemotropic axon guidance molecules in tumorigenesis, *Prog. Exp. Tumor Res.* 39 (2007) 78–90.
- [39] L. Capparuccia, L. Tamagnone, Semaphorin signaling in cancer cells and in cells of the tumor microenvironment—two sides of a coin, *J. Cell Sci.* 122 (2009) 1723–1736.
- [40] Z.Q. Hu, S.L. Zhou, Z.J. Zhou, C.B. Luo, E.B. Chen, H. Zhan, P.C. Wang, Z. Dai, J. Zhou, J. Fan, X.W. Huang, Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection, *Oncotarget* 7 (2016) 51733–51746.
- [41] C. Jayakumar, P. Ranganathan, P. Devarajan, C.D. Krawczeski, S. Looney, G. Ramesh, Semaphorin 3A is a new early diagnostic biomarker of experimental and pediatric acute kidney injury, *PLoS One* 8 (2013), e58446.

- [42] L. Lewandowska, J. Matuszkiewicz-Rowinska, C. Jayakumar, U. Oldakowska-Jedynak, S. Looney, M. Galas, M. Dutkiewicz, M. Krawczyk, G. Ramesh, Netrin-1 and semaphorin 3A predict the development of acute kidney injury in liver transplant patients, *PLoS One* 9 (2014), e107898.
- [43] N. Morishige, J.A. Ko, Y. Liu, T. Chikama, T. Nishida, Localization of semaphorin 3A in the rat cornea, *Exp. Eye Res.* 86 (2008) 669–674.
- [44] M.K. Do, N. Shimizu, T. Suzuki, H. Ohtsubo, W. Mizunoya, M. Nakamura, S. Sawano, M. Furuse, Y. Ikeuchi, J.E. Anderson, R. Tatsumi, Transmembrane proteoglycans syndecan-2, 4, receptor candidates for the impact of HGF and FGF2 on semaphorin 3A expression in early-differentiated myoblasts, *Phys. Rep.* 3 (2015).
- [45] Y. Glinka, S. Stoilova, N. Mohammed, G.J. Prud'homme, Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta, *Carcinogenesis* 32 (2011) 613–621.
- [46] H.B. Hindman, M. DeMagistris, C. Callan, T. McDaniel, T. Bubel, K.R. Huxlin, Impact of topical anti-fibrotics on corneal nerve regeneration in vivo, *Exp. Eye Res.* 181 (2019) 49–60.